Analyst Justin Walsh from JonesTrading reiterated a Buy rating on NeuroOne Medical Technologies and decreased the price target to $8.00 from $9.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Justin Walsh has given his Buy rating due to a combination of factors, including the updated valuation following NeuroOne’s 1-for-6 reverse stock split. After adjusting share counts and projected equity raise prices, his risk-adjusted discounted cash flow model points to a fair market value around $116 million and supports a revised $8 per-share target despite the mechanical nature of the change.
Walsh also highlights the company’s partner-driven strategy for commercializing its RF ablation system, which he believes can underpin a recurring revenue stream and drive a path to profitability. He further sees upside from the pipeline, notably the sEEG-based drug delivery platform and spinal cord percutaneous paddle lead, along with a cash position that management projects will fund operations into fiscal 2026, collectively justifying a continued Buy stance.
According to TipRanks, Walsh is a 5-star analyst with an average return of 20.7% and a 38.69% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Beyond Air, and Rapport Therapeutics, Inc..